Healthcare / Medical DevicesShanghai
$55.88
-2.62 (-4.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-73.6M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-0.8%
↓Gross Margin
36.6%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.2%
FCF CAGR
—
FCF margin
-43.1%
FCF / Net income
20.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $320.9M · net income $-6.7M · FCF $-138.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $320.9M | $320.9M | $298.1M | $273.7M | $204.6M |
| Net Income | $-6.7M | $-6.7M | $17.7M | $15.4M | $-5.6M |
| EBITDA | $-1.3M | $-1.3M | $26.3M | $25.5M | $-197156.90 |
| EPS | -0.08 | -0.08 | 0.20 | 0.17 | -0.06 |
| Gross Margin | 36.6% | 36.6% | 39.5% | 39.0% | 36.6% |
| Operating Margin | 6.2% | 6.2% | 5.8% | 2.8% | -10.1% |
| Net Margin | -2.1% | -2.1% | 5.9% | 5.6% | -2.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.02 | 0.02 | 0.01 |
| Current Ratio | 4.66 | 4.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-138.4M | $-138.4M | $-73.6M | $-21.7M | $-55.9M |
| Returns | |||||
| ROE | -0.8% | -0.8% | 2.0% | 1.8% | -0.7% |
| Valuation | |||||
| P/E | — | — | 63.80 | 117.53 | — |
| EV/EBITDA | — | — | 33.12 | 61.95 | — |
| P/B | 5.45 | 5.45 | 1.31 | 2.11 | 2.32 |
| Growth & Yield | |||||
| Revenue Growth | 7.6% | 7.6% | 8.9% | 33.8% | — |
| EPS Growth | -140.0% | -140.0% | 17.6% | 383.3% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+206.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.20 → -0.08
Residual
+206.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.